Clinical reference Biomarker Directory
Back to directory

Phosphofructokinase

Emerging

PFK deficiency (Tarui disease) uniquely combines hemolytic anemia with a muscle glycogen storage disease.

Also known as PFK PFKM Tarui disease enzyme
In plain language

This enzyme deficiency (called Tarui disease) is unusual because it affects both red blood cells, causing anemia, and muscles, causing exercise-related cramping — a combined pattern not seen with the other similar enzyme deficiencies in this set.

Biomarker & context

Phosphofructokinase (PFK) is a key regulatory enzyme in glycolysis; its deficiency affects both red blood cells and muscle tissue, causing a distinct combined syndrome.

What it indicates

PFK deficiency (Tarui disease) causes both hereditary hemolytic anemia and a muscle glycogen storage disease, presenting with exercise intolerance and muscle cramping in addition to the anemia seen with other glycolytic enzyme deficiencies discussed in this biomarker set.

Diagnosis & clinical testing

Diagnosed via red blood cell and muscle enzyme activity assays, with genetic testing of the PFKM gene confirming diagnosis; the combined muscle and blood involvement distinguishes it from the other glycolytic enzyme deficiencies in this set, which are typically blood-only.

Guiding treatment

Management includes avoiding high-intensity exercise (to prevent muscle symptoms) and supportive anemia management (transfusions as needed), since no enzyme-specific therapy exists for this rare combined disorder.

Clinical significance

The combined blood and muscle involvement distinguishes it from other glycolytic enzyme deficiencies in this biomarker set.

References
  1. General metabolic disease reference literature on phosphofructokinase deficiency (Tarui disease).